FBIO (Fortress Biotech) Moat Score: 3/10 (As of Jun. 30, 2026)


FBIO Fortress Biotech Inc FBIO
44 GF Score
Price $2.95
GF Value $1.23
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Fortress Biotech Moat Score?

Fortress Biotech FBIO +7.66% 44 Moat Score is 3 as of Jun. 30, 2026. GuruFocus rates FBIO with a GF Score™ of 44/100 and a GF Value™ of $1.23 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,401 Biotechnology companies, Fortress Biotech ranks better than 75.52% on this metric.

Fortress Biotech has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Fortress Biotech has No Moat: Fortress Biotech Inc lacks significant market leadership, customer switching costs, and valuable intellectual property. It does not possess strong brand strength or durable cost advantages, and there are no significant regulatory barriers or exclusive licenses, resulting in a very weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Fortress Biotech might have No Moat - Very weak/transient advantages.

Fortress Biotech  (NAS:FBIO) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Fortress Biotech Moat Score Related Terms

FBIO vs RLYB, INO, SEER: Moat Score Comparison

For the Biotechnology subindustry, Fortress Biotech's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fortress Biotech Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Moat Score distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Moat Score falls into.


FBIO
44GF Score
Fortress Biotech Inc FBIO
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Fortress Biotech (FBIO) has a Moat Score of 3 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Fortress Biotech ranks #343 out of 1401 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Fortress Biotech's Moat Score too high?
Fortress Biotech's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Fortress Biotech's value of 3 is 50% above this industry median. Based on the distribution chart, Fortress Biotech ranks #343 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Fortress Biotech has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fortress Biotech's Moat Score compare to RLYB and INO?
According to the Biotechnology industry distribution chart, Fortress Biotech ranks #343 out of 1401 companies for Moat Score. This places Fortress Biotech in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Fortress Biotech's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fortress Biotech's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fortress Biotech's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortress Biotech stock overvalued right now?
Based on GuruFocus' analysis, Fortress Biotech (FBIO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.23, compared to a current price of $2.95 — trading 139.4% above its estimated fair value. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Fortress Biotech's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Fortress Biotech (FBIO), the current Moat Score is 3 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fortress Biotech (FBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Fortress Biotech stock appears to be overvalued. The current stock price of $2.95 is trading 139.4% above its estimated GF Value™ of $1.23. GuruFocus considers Fortress Biotech to be Significantly Overvalued.

Key valuation signals for FBIO:

  • Moat Score: 3
  • GF Value™: $1.23 vs. price of $2.95 (139.4% above fair value)
  • GF Score™: 44/100 with 6 warning signs
  • Industry Position: 50% above the Biotechnology median (#343 of 1401)

No single metric tells the full story. See the FBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fortress Biotech Business Description

Address 1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
44GF Score

Get the complete analysis for FBIO

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.95
Price
$1.23
GF Value